You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
Progenetics will distribute GeneStrat and Veristrat liquid biopsy tests in Israel, making Biodesix's tests available in the Middle East for the first time.
The company plans to use the proceeds to support research collaborations and to expand its commercial team.
The two studies were part of larger project aimed at building a complete map of mitochondrial function and associated proteins.
The results support a survival benefit for patients treated with therapies guided by combined DNA and mRNA sequencing and protein expression analyses.
The assay is designed to measure changes in blood levels of the peptide precursor procalcitonin to differentiate bacterial infections from viral ones.
Researchers also uncovered key pathways and alterations linked to differences in survival.
Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.
The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
The company said it plans to launch a clinical trial to validate its Immray PanCan-d blood test in both Europe and the US.
While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.
The decision lets Vermillion access Medi-Cal's patient network, which covers more than 12.6 million lives, or roughly a third of California's covered lives.
In a large, prospective study published in Lancet Oncology, the screening assay was projected to reduce the number of prostate biopsies by 32 percent.
The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The deal provides Sciex with the rights to commercialize immune-MRM technology developed by Amanda Paulovich's laboratory.
OncoPlex operates a CAP-accredited and CLIA-certified laboratory and provides mass spectrometry-based tumor profiling services.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.